HealthDay News — Liquid-based cytology (LBC) and human papillomavirus (HPV) cotesting enhances screening for cervical cancer and precancer among women aged ≥30 years, according to a study published online in the American Journal of Clinical Pathology.
Dr Harvey W. Kaufman from Quest Diagnostics in Secaucus, New Jersey, and colleagues examined the results of LBC/HPV cotesting in 13,633,071 women aged ≥30 years, tested in 2010 to 2018.
The researchers found that 1615 cotests preceded 1259 cervical cancer diagnoses and 11,164 cotests preceded 8048 cervical precancer diagnoses among all screening results. Compared with the HPV result, the LBC result identified more women who were subsequently diagnosed with cervical cancer within one year (85.1% vs 77.5%). The overall rate of nondetection was 13.1% for cotesting results (LBC negative/HPV negative) among all women with cervical cancer; when testing exceeded 12 months prediagnosis of cervical cancer or precancer, this rate increased substantially compared with testing within one year.
“For women who may otherwise not be screened at all, there is no question that cytology or HPV primary are useful screening technologies,” a coauthor said in a statement. “Yet, that should not obscure the fact that cotesting is fundamentally the better screening option for women and is widely available in the US”
Several authors disclosed financial ties to Quest Diagnostics.